Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Alarcon, 2005, Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid, J. Biol. Chem., 280, 30406
Anzai, 2006, Protracted juvenile neuronal ceroid lipofuscinosis—an autopsy report and immunohistochemical analysis, Brain Dev., 28, 462, 10.1016/j.braindev.2005.12.004
Behl, 1994, Hydrogen peroxide mediates amyloid beta protein toxicity, Cell, 77, 817, 10.1016/0092-8674(94)90131-7
Berbaum, 2008, Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array, Cytokine, 41, 198, 10.1016/j.cyto.2007.11.012
Bierhaus, 2005, Understanding RAGE, the receptor for advanced glycation end products, J. Mol. Med., 83, 876, 10.1007/s00109-005-0688-7
Bigl, 2008, Cytotoxicity of advanced glycation endproducts in human micro- and astroglial cell lines depends on the degree of protein glycation, J. Neural Transm., 115, 1545, 10.1007/s00702-008-0126-4
Blatnik, 2008, Inactivation of glyceraldehyde-3-phosphate dehydrogenase by fumarate in diabetes: formation of S-(2-succinyl)cysteine, a novel chemical modification of protein and possible biomarker of mitochondrial stress, Diabetes, 57, 41, 10.2337/db07-0838
Braak, 1988, Neuropil threads occur in dendrites of tangle-bearing nerve cells, Neuropathol. Appl. Neurobiol., 14, 39, 10.1111/j.1365-2990.1988.tb00864.x
Brett, 1993, Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues, Am. J. Pathol., 143, 1699
Brownlee, 1995, Advanced protein glycosylation in diabetes and aging, Annu. Rev. Med., 46, 223, 10.1146/annurev.med.46.1.223
Bucciarelli, 2002, RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease, Cell. Mol. Life Sci., 59, 1117, 10.1007/s00018-002-8491-x
Bucht, 1983, Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type, Acta Med. Scand., 213, 387, 10.1111/j.0954-6820.1983.tb03756.x
Carini, 2003, Acrolein-sequestering ability of endogenous dipeptides: characterization of carnosine and homocarnosine/acrolein adducts by electrospray ionization tandem mass spectrometry, J. Mass Spectrom., 38, 996, 10.1002/jms.517
Carubelli, 1995, Cytotoxic effects of autoxidative glycation, Free Radic. Biol. Med., 18, 265, 10.1016/0891-5849(94)E0134-5
Casselmann, 2004, Age-dependent expression of advanced glycation end product receptor genes in the human heart, Gerontology, 50, 127, 10.1159/000076770
Chen, 2007, RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease, Curr. Mol. Med., 7, 735, 10.2174/156652407783220741
Cho, 2005, The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia, J. Neurosci., 25, 2504, 10.1523/JNEUROSCI.0035-05.2005
Chou, 2004, Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration, J. Neurochem., 90, 1389, 10.1111/j.1471-4159.2004.02609.x
Clynes, 2007, Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response, Curr. Mol. Med., 7, 743, 10.2174/156652407783220714
Cochrane, 1993, The role of bound lipid and transition metal in the formation of fluorescent advanced glycation endproducts by human serum albumin, Biochem. Soc. Trans., 21, 97S, 10.1042/bst021097s
de Arriba, 2003, Advanced glycation endproducts induce changes in glucose consumption, lactate production, and ATP levels in SH-SY5Y neuroblastoma cells by a redox-sensitive mechanism, J. Cereb. Blood Flow Metab., 23, 1307, 10.1097/01.WCB.0000090622.86921.0E
Deane, 2003, RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain, Nat. Med., 9, 907, 10.1038/nm890
Deuther-Conrad, 2001, Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism, Neurosci. Lett., 312, 29, 10.1016/S0304-3940(01)02174-7
Donahue, 2006, RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease, Acta Neuropathol. (Berl.), 112, 405, 10.1007/s00401-006-0115-3
Donato, 2001, S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles, Int. J. Biochem. Cell Biol., 33, 637, 10.1016/S1357-2725(01)00046-2
Drinda, 2004, Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis, Rheumatol. Int., 25, 411, 10.1007/s00296-004-0456-y
Du, 2003, Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells, J. Clin. Invest., 112, 1049, 10.1172/JCI18127
Du Yan, 1997, Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease, Proc. Natl. Acad. Sci. U.S.A., 94, 5296, 10.1073/pnas.94.10.5296
Dukic-Stefanovic, 2003, Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs), J. Neurochem., 87, 2609, 10.1046/j.1471-4159.2003.01988.x
Dukic-Stefanovic, 2003, Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs), J. Neurochem., 87, 44, 10.1046/j.1471-4159.2003.01988.x
Emanuele, 2005, Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia, Arch. Neurol., 62, 1734, 10.1001/archneur.62.11.1734
Falcone, 2005, Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men, Arterioscler. Thromb. Vasc. Biol., 25, 1032, 10.1161/01.ATV.0000160342.20342.00
Fonteh, 2007, Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects, Amino Acids, 32, 213, 10.1007/s00726-006-0409-8
Franke, 2007, Advanced glycation endproducts influence the mRNA expression of RAGE RANKL and various osteoblastic genes in human osteoblasts, Arch. Physiol. Biochem., 113, 154, 10.1080/13813450701602523
Fujisawa, 1991, Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type, Biol. Psychiatry, 30, 1219, 10.1016/0006-3223(91)90158-I
Gasic-Milenkovic, 2001, Protein “AGEing”—cytotoxicity of a glycated protein increases with its degree of AGE-modification, Z. Gerontol. Geriatr., 34, 457, 10.1007/s003910170018
Gasic-Milenkovic, 2003, beta-Amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon-gamma and ‘advanced glycation endproducts’ in a murine microglia cell line, Eur. J. Neurosci., 17, 813, 10.1046/j.1460-9568.2003.02506.x
Gasser, 2008, Advanced glycation: implications in tissue damage and disease, Protein Pept. Lett., 15, 385, 10.2174/092986608784246515
Gerdemann, 2000, Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis, Clin. Nephrol., 54, 276
Geroldi, 2005, Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension, J. Hypertens., 23, 1725, 10.1097/01.hjh.0000177535.45785.64
Geroldi, 2006, Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target, Curr. Med. Chem., 13, 1971, 10.2174/092986706777585013
Ghidoni, 2008, Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment, J. Neural Transm., 115, 1047, 10.1007/s00702-008-0069-9
Girones, 2004, N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease, Free Radic. Biol. Med., 36, 1241, 10.1016/j.freeradbiomed.2004.02.006
Gohda, 2008, Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function, Diabetes Res. Clin. Pract., 81, 196, 10.1016/j.diabres.2008.04.013
Gotz, 2001, Tau and transgenic animal models, Brain Res. Rev., 35, 266, 10.1016/S0165-0173(01)00055-8
Haass, 1994, Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor, J. Biol. Chem., 269, 17741, 10.1016/S0021-9258(17)32503-6
Heizmann, 2007, Pathologies involving the S100 proteins and RAGE, Subcell. Biochem., 45, 93, 10.1007/978-1-4020-6191-2_5
Hickman, 2008, Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice, J. Neurosci., 28, 8354, 10.1523/JNEUROSCI.0616-08.2008
Hipkiss, 2007, Could carnosine or related structures suppress Alzheimer's disease?, J. Alzheimers Dis., 11, 229, 10.3233/JAD-2007-11210
Horie, 1997, Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons, Biochem. Biophys. Res. Commun., 236, 327, 10.1006/bbrc.1997.6944
Hoyer, 1998, Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis, J. Neural Transm., 105, 415, 10.1007/s007020050067
Hoyer, 2004, Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications, Adv. Exp. Med. Biol., 541, 135, 10.1007/978-1-4419-8969-7_8
Hudson, 2003, Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders, Arch. Biochem. Biophys., 419, 80, 10.1016/j.abb.2003.08.030
Hudson, 2008, Identification, classification, and expression of RAGE gene splice variants, FASEB J., 22, 1572, 10.1096/fj.07-9909com
Humpert, 2007, Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes, Cardiovasc. Diabetol., 6, 9, 10.1186/1475-2840-6-9
Iwata, 2004, Effect of carbonyl compounds on red blood cells deformability, Biochem. Biophys. Res. Commun., 321, 700, 10.1016/j.bbrc.2004.07.026
Jerums, 2003, Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease, Arch. Biochem. Biophys., 419, 55, 10.1016/j.abb.2003.08.017
Jeynes, 2008, Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis, Curr. Alzheimer Res., 5, 432, 10.2174/156720508785908937
Kimura, 1995, Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease?, Neuroreport, 6, 866, 10.1097/00001756-199504190-00010
Ko, 1999, An immunochemical study on tau glycation in paired helical filaments, Brain Res., 830, 301, 10.1016/S0006-8993(99)01415-8
Kodl, 2008, Cognitive dysfunction and diabetes mellitus, Endocr. Rev., 29, 494, 10.1210/er.2007-0034
Kuhla, 2004, Differential effects of “Advanced glycation endproducts” and beta-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y, J. Neural Transm., 111, 427, 10.1007/s00702-003-0038-2
Ledesma, 1994, Analysis of microtubule-associated protein tau glycation in paired helical filaments, J. Biol. Chem., 269, 21614, 10.1016/S0021-9258(17)31849-5
Lichtenthaler, 1997, Mutations in the transmembrane domain of APP altering gamma-secretase specificity, Biochemistry, 36, 15396, 10.1021/bi971071m
Loske, 1998, Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress, J. Neural Transm., 105, 1005, 10.1007/s007020050108
Loske, 2000, Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide, Eur. J. Biochem., 267, 4171, 10.1046/j.1432-1327.2000.01452.x
Lotze, 2005, High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal, Nat. Rev. Immunol., 5, 331, 10.1038/nri1594
Lovell, 1998, Copper, iron and zinc in Alzheimer's disease senile plaques, J. Neurol. Sci., 158, 47, 10.1016/S0022-510X(98)00092-6
Lue, 2001, Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism, Exp. Neurol., 171, 29, 10.1006/exnr.2001.7732
Lüth, 2005, Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains, Cereb. Cortex, 15, 211, 10.1093/cercor/bhh123
Mackic, 2002, Circulating amyloid-beta peptide crosses the blood–brain barrier in aged monkeys and contributes to Alzheimer's disease lesions, Vascul. Pharmacol., 38, 303, 10.1016/S1537-1891(02)00198-2
Martel, 1996, Blood–brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs, Neurosci. Lett., 206, 157, 10.1016/S0304-3940(96)12462-9
Miyata, 1997, Accumulation of pyrraline-modified albumin in phagocytes due to reduced degradation by lysosomal enzymes, J. Biol. Chem., 272, 4037, 10.1074/jbc.272.7.4037
Monnier, 1981, Nonenzymatic browning in vivo: possible process for aging of long-lived proteins, Science, 211, 491, 10.1126/science.6779377
Muhlemann, 2008, Recognition and elimination of nonsense mRNA, Biochim. Biophys. Acta, 1779, 538, 10.1016/j.bbagrm.2008.06.012
Mullarkey, 1990, Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes, Biochem. Biophys. Res. Commun., 173, 932, 10.1016/S0006-291X(05)80875-7
Münch, 1997, Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide, Biochim. Biophys. Acta, 1360, 17, 10.1016/S0925-4439(96)00062-2
Münch, 1997, Advanced glycation endproducts in ageing and Alzheimer's disease, Brain Res. Rev., 23, 134, 10.1016/S0165-0173(96)00016-1
Münch, 1999, Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library, Nat. Biotechnol., 17, 1006, 10.1038/13704
Muscat, 2007, Coffee and Maillard products activate NF-kappaB in macrophages via H(2)O(2) production, Mol. Nutr. Food Res., 51, 525, 10.1002/mnfr.200600254
Nakamura, 2007, Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes, Mol. Med., 13, 185, 10.2119/2006-00090.Nakamura
Neeper, 1992, Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins, J. Biol. Chem., 267, 14998, 10.1016/S0021-9258(18)42138-2
Nitti, 2007, PKC delta and NADPH oxidase in AGE-induced neuronal death, Neurosci. Lett., 416, 261, 10.1016/j.neulet.2007.02.013
Ortwerth, 1998, The generation of superoxide anions in glycation reactions with sugars, osones, and 3-deoxyosones, Biochem. Biophys. Res. Commun., 245, 161, 10.1006/bbrc.1998.8401
Ott, 1999, Diabetes mellitus and the risk of dementia: the Rotterdam Study, Neurology, 53, 1937, 10.1212/WNL.53.9.1937
Pepeu, 1989, Nootropic drugs and brain cholinergic mechanisms, Prog. Neuropsychopharmacol. Biol. Psychiatry, S77, 10.1016/0278-5846(89)90112-7
Price, 2001, Chelating activity of advanced glycation end-product inhibitors, J. Biol. Chem., 276, 48967, 10.1074/jbc.M108196200
Rahbar, 2000, Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation, Clin. Chim. Acta, 301, 65, 10.1016/S0009-8981(00)00327-2
Rahbar, 2000, Novel inhibitors of advanced glycation endproducts (part II), Mol. Cell Biol. Res. Commun., 3, 360, 10.1006/mcbr.2000.0239
Raucci, 2008, A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10), FASEB J., 22, 3716, 10.1096/fj.08-109033
Rauvala, 2007, RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease, Curr. Mol. Med., 7, 725, 10.2174/156652407783220750
Reddy, 2005, Carnosine: a versatile antioxidant and antiglycating agent, Sci. Aging Knowledge Environ., pe12
Rogers, 2007, Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?, Int. Rev. Neurobiol., 82, 235, 10.1016/S0074-7742(07)82012-5
Saletu, 1989, Psychophysiological research in psychiatry and neuropsychopharmacology II. The investigation of antihypoxidotic/nootropic drugs (tenilsetam and co-dergocrine-mesylate) in elderlies with the Viennese Psychophysiological Test-System (VPTS), Methods Find. Exp. Clin. Pharmacol., 11, 43
Salkovic-Petrisic, 2007, Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach, J. Neural Transm. Suppl., 217
Sasaki, 1998, Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases, Am. J. Pathol., 153, 1149, 10.1016/S0002-9440(10)65659-3
Schmidt, 1994, Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins, Proc. Natl. Acad. Sci. U.S.A., 91, 8807, 10.1073/pnas.91.19.8807
Schmidt, 2005, Drug development and PET-diagnostics for Alzheimer's disease, Curr. Med. Chem., 12, 1677, 10.2174/0929867054367130
Schubert, 2005, Glucose metabolism and Alzheimer's disease, Ageing Res. Rev., 4, 240, 10.1016/j.arr.2005.02.003
Sebekova, 1998, Advanced glycated albumin impairs protein degradation in the kidney proximal tubules cell line LLC-PK1, Cell. Mol. Biol. (Noisy-le-grand), 44, 1051
Shoda, 1997, Inhibitory effects of tenilsetam on the Maillard reaction, Endocrinology, 138, 1886, 10.1210/endo.138.5.5151
Simard, 2006, Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease, Neuron, 49, 489, 10.1016/j.neuron.2006.01.022
Smith, 1994, Alzheimer disease: an imbalance of proteolytic regulation?, Med. Hypotheses, 42, 277, 10.1016/0306-9877(94)90132-5
Smith, 1995, Amyloidosis, advanced glycation end products and Alzheimer disease, Neuroreport, 6, 1595, 10.1097/00001756-199508000-00001
Smith, 1996, Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link, Diabetologia, 39, 247, 10.1007/BF00403972
Smith, 1996, Early contribution of oxidative glycation in Alzheimer disease, Neurosci. Lett., 217, 210, 10.1016/0304-3940(96)13100-1
Steele, 2007, The molecular basis of the prevention of Alzheimer's disease through healthy nutrition, Exp. Gerontol., 42, 28, 10.1016/j.exger.2006.06.002
Sternberg, 2008, Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity, Mult. Scler., 14, 759, 10.1177/1352458507088105
Stolzing, 2006, Degradation of glycated bovine serum albumin in microglial cells, Free Radic. Biol. Med., 40, 1017, 10.1016/j.freeradbiomed.2005.10.061
Sugaya, 1994, Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3, Genomics, 23, 408, 10.1006/geno.1994.1517
Takedo, 1996, Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain, Neurosci. Lett., 221, 17, 10.1016/S0304-3940(96)13275-4
Takeuchi, 2008, Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease, Curr. Pharm. Des., 14, 973, 10.2174/138161208784139693
Tan, 1998, Presenilin-1 mutations associated with familial Alzheimer's disease do not disrupt protein transport from the endoplasmic reticulum to the Golgi apparatus, Biochim. Biophys. Acta, 1407, 69, 10.1016/S0925-4439(98)00031-3
Tanaka, 2000, The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells, J. Biol. Chem., 275, 25781, 10.1074/jbc.M001235200
Thomas, 2005, The role of AGEs and AGE inhibitors in diabetic cardiovascular disease, Curr. Drug Targets, 6, 453, 10.2174/1389450054021873
Thornalley, 2003, Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts, Arch. Biochem. Biophys., 419, 31, 10.1016/j.abb.2003.08.013
Thorpe, 1996, Role of the Maillard reaction in diabetes mellitus and diseases of aging, Drugs Aging, 9, 69, 10.2165/00002512-199609020-00001
Toth, 2007, RAGE, diabetes, and the nervous system, Curr. Mol. Med., 7, 766, 10.2174/156652407783220705
Ueda, 1994, Amyloid beta protein-induced neuronal cell death: neurotoxic properties of aggregated amyloid beta protein, Brain Res., 639, 240, 10.1016/0006-8993(94)91736-1
Vitek, 1994, Advanced glycation end products contribute to amyloidosis in Alzheimer disease, Proc. Natl. Acad. Sci. U.S.A., 91, 4766, 10.1073/pnas.91.11.4766
Wolf, 2002, Oxidative DNA damage as a marker of aging in WI-38 human fibroblasts, Exp. Gerontol., 37, 647, 10.1016/S0531-5565(02)00005-0
Wong, 2001, Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia, Eur. J. Neurosci., 14, 1961, 10.1046/j.0953-816x.2001.01820.x
Xia, 1997, Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins, J. Biol. Chem., 272, 7977, 10.1074/jbc.272.12.7977
Yan, 1994, Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress, Proc. Natl. Acad. Sci. U.S.A., 91, 7787, 10.1073/pnas.91.16.7787
Yan, 1996, RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease, Nature, 382, 685, 10.1038/382685a0
Yan, 1996, RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease, Nature, 382, 685, 10.1038/382685a0
Yesavage, 2002, Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment, J. Psychiatr. Res., 36, 281, 10.1016/S0022-3956(02)00020-1
Yonekura, 2003, Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury, Biochem. J., 370, 1097, 10.1042/bj20021371
Zeng, 2004, Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice, Hepatology, 39, 422, 10.1002/hep.20045
Zhang, 2008, Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases, J. Biol. Chem., 283, 35507, 10.1074/jbc.M806948200
Zlokovic, 2008, New therapeutic targets in the neurovascular pathway in Alzheimer's disease, Neurotherapeutics, 5, 409, 10.1016/j.nurt.2008.05.011
Zlokovic, 1985, Blood–brain barrier permeability to leucine-enkephalin d-alanine2-d-leucine5-enkephalin and their N-terminal amino acid (tyrosine), Brain Res., 336, 125, 10.1016/0006-8993(85)90423-8